Daniel Spiegelman
Equibles does not estimate personal net worth.
Get an email with a short summary when Biomarin Pharmaceutical Inc publishes a filing, an earnings call transcript or a press release.
Get BMRN alertsAbout Daniel Spiegelman
Daniel Spiegelman is recorded as CFO at Biomarin Pharmaceutical Inc (BMRN). The proxy statement of Biomarin Pharmaceutical Inc reports total compensation of $5,239,902 for Daniel Spiegelman in fiscal 2019, including a base salary of $620,192. Disclosed compensation is on record for 3 fiscal years. Biomarin Pharmaceutical Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Biomarin Pharmaceutical Inc includes Alexander Hardy (CEO and Board Member), Richard A. Meier (Chairman), Brian Mueller (CFO) and 7 others.
Affiliation history
-
Current
Company network
Leadership on record at Biomarin Pharmaceutical Inc
- Alexander Hardy CEO, Board Member
- Richard A. Meier Chairman
- Brian Mueller CFO
- Dr. C. Greg Guyer CTO
- G. Eric Davis General Counsel
- Andrea Acosta Chief Accounting Officer
- Rashmi Ramchandani Chief Accounting Officer
- Athena Countouriotis Board Member
- Barbara Bodem Board Member
- Barbara W. Bodem Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2019 | Biomarin Pharmaceutical Inc (BMRN) | Former Executive Vice President, Chief Financial Officer | $620,192 | $5,239,902 |
| 2018 | Biomarin Pharmaceutical Inc (BMRN) | Former Executive Vice President, Chief Financial Officer | $593,269 | $4,521,703 |
| 2017 | Biomarin Pharmaceutical Inc (BMRN) | Former Executive Vice President, Chief Financial Officer | $559,231 | $4,641,875 |
Recent activity
No call appearances or filed executive changes recorded yet.